ImmVirX Announces $22 Million Series A Financing
Proceeds to accelerate development of receptor targeted oncolytic RNA viruses Clinical studies of lead candidate IVX 037 expected Q1 2022 Melbourne, Australia 14th May 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and […]
